Skip to main content

Table 4 Risk factors for 28-day mortality among 36 patients infected by tigecycline non-susecptible K. pneumoniae bacteremia

From: Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in Taiwan

  Survivors (n = 22), n (%) Non-survivors (n = 14), n (%) p Adjustedpa
Age (years, median, IQR) 76.5, 69.3–84.3 71, 60.3–79 0.175  
Male sex 17 (77.3) 10 (71.4) 0.988  
Underlying disease     
 Immunosuppressionb 5 (22.7) 4 (28.6) 0.988  
 Diabetes mellitus 9 (40.9) 9 (64.3) 0.305  
 Chronic obstructive lung disease 2 (9.1) 3 (21.4) 0.574  
 Hemodialysis 5 (22.7) 6 (42.9) 0.364  
 Malignancy 7 (31.8) 7 (50) 0.458  
 Liver cirrhosis 2 ( 9.1) 1 (7.1) 1.000  
 Cerebral vascular disease 6 (27.3) 4 (28.6) 1.000  
 Charlson comorbidity score (median, IQR) 3, 2–5 4, 3–8.3 0.171  
Pitt bacteremia score (mean ± SD) 3.3 ± 3.1 5.9 ± 3.7 0.037 0.847
APACHE II score (mean ± SD) 20.1 ± 0.6 27.6 ± 11.0 0.016 0.958
Acquired after ICU >48 h 3 (13.6) 11 (78.6) <0.001 0.021
Infection sources and clinical syndrome     
 Pneumonia 3 (13.6) 7 (50) 0.047 0.569
 Intra-abdominal infection other than biliary-tract infection 2 (9.1) 3 (21.4) 0.574  
 Biliary-tract infection 7 (31.8) 0 (0)   
 Unknown primary focus 8 (36.4) 2 (14.3) 0.289  
Presentation with septic shock 9 (40.9) 10 (71.4) 0.147  
Appropriate antibiotic treatment 12 (54.6) 6 (42.9) 0.733  
Ertapenem non-susceptibility 6 (27.3) 2 (14.3) 0.628  
Tigecycline MIC >4 μg/mL 10 (45.5) 8 (57.1) 0.733  
Tigecycline MIC >6 μg/mL 4 (18.2) 6 (42.9) 0.220  
ESBL-producing strain 10 (45.5) 8 (57.1) 0.733  
  1. IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.
  2. aAll factors with p < 0.1 in univariate analyses were included in the exact logistic regression.
  3. bImmunosuppression includes patients who underwent solid-organ transplantation, corticosteroid therapy, and immunosuppression therapy.